EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte Studie

N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial

Kirsten C Morley iD, Siena Peruch, Claire Adams, Ellen Towers, Chris Tremonti, Joshua Watt, Nazila Jamshidi, Paul S Haber

Alcohol and Alcoholism · 2023

DOI: 10.1093/alcalc/agad044 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Alcohol and Alcoholism, 2023. Verfasst von Kirsten C Morley und 7 weiteren Autor:innen. Beteiligte Einrichtung: Specialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, NSW, Australia. Hauptthemen laut MEDLINE: Acetylcysteine, Alcoholism. Die Arbeit wurde bisher 24-mal zitiert (Crossref) und nennt 42 Literaturangaben. Gefördert von: MRFF Practitioner Fellowship, Moyira Elizabeth Vine Fund for Research into Schizophrenia Scheme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

N-acetyl cysteine (NAC) is a potent antioxidant that modulates glutamatergic signalling which is thought to play a role in alcohol use disorder (AUD). There have been no clinical trials investigating NAC for AUD. We aimed to conduct a 28 day double-blind, placebo-controlled (PL) randomized trial of NAC in the treatment of AUD (NCT03879759). A total of 42 participants with AUD (56% alcohol-related liver disease) were randomized to receive placebo or NAC 2400 mg/day. Feasibility outcomes included treatment retention and adverse events. Primary clinical outcomes included alcohol consumption (heavy drinking days, standard drinks per drinking day). Secondary clinical outcome measures included craving, liver tests, and psychological outcomes. There were no significant differences in overall retention between treatment groups (χ2(1) = 0.14, P = 0.71: 86% vs 76% for placebo and NAC, respectively). The most commonly reported adverse event in NAC-treated individuals included headache (14%). For standard drinks per drinking day, there was a significant overall effect of time (F = 9.18, P < 0.001), no significant effect of treatment (F = 0.75, P = 0.79), and a significant time x treatment (NAC vs PL) effect (F = 2.73, P < 0.05). For number of heavy drinks per day, there was a significant overall effect of time (F = 3.16, P < 0.05) but no significant effect of treatment or time x treatment (P = 0.17). There were no significant NAC vs PL effects on secondary clinical outcome measures. In the first trial of NAC for the management of AUD, NAC appears to be feasible and safe. Although there was a significant effect of NAC vs placebo on some alcohol measures such as drinks per drinking day, there does appear to be a variable pattern of effect across time suggesting that a larger trial incorporating a longer treatment duration is now required to determine efficacy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AcetylcysteineAlcoholismHumansDouble-Blind MethodTreatment OutcomeMaleFemaleAdultMiddle AgedAged

Stichwörter der Autor:innen

ClinicalTrials.gov Identifier: NCT03879759N acetylcysteinealcohol dependencealcohol use disorderalcohol-related liver diseasepharmacotherapyrandomized-controlled trial

Substanzen

Acetylcysteine

Autor:innen und Institutionen

  • Specialty of Addiction Medicine, Sydney Medical School, Faculty of Medicine and Health, University of Sydney, NSW, Australia.
  • Edith Collins Centre for Translational Research, Level6, KGV Buidling, Missenden Road, Sydney Local Health District, Royal Prince Alfred Hospital, NSW, Australia.

ORCID-Profile: Kirsten C Morley

Förderung

  • MRFF Practitioner Fellowship
  • Moyira Elizabeth Vine Fund for Research into Schizophrenia Scheme

Zitieren

APA

Morley, K. C., Peruch, S., Adams, C., Towers, E., Tremonti, C., Watt, J., Jamshidi, N., & Haber, P. S. (2023). N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism. https://doi.org/10.1093/alcalc/agad044

Vancouver

Morley KC, Peruch S, Adams C, Towers E, Tremonti C, Watt J, et al. N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial. Alcohol and Alcoholism. 2023. doi:10.1093/alcalc/agad044

BibTeX
@article{Morley2023,
  author = {Morley, Kirsten C and Peruch, Siena and Adams, Claire and Towers, Ellen and Tremonti, Chris and Watt, Joshua and Jamshidi, Nazila and Haber, Paul S},
  title = {N acetylcysteine in the treatment of alcohol use disorder: a randomized, double-blind, placebo-controlled trial},
  journal = {Alcohol and Alcoholism},
  year = {2023},
  doi = {10.1093/alcalc/agad044}
}
Kostenlos starten →